This protocol covers type I cryoglobulinemia arising in the setting of an underlying B-cell lymphoma, specifically Waldenström macroglobulinemia, where a monoclonal IgM cryoglobulin is the driving pathology.
Clinical scenario: Type I cryoglobulinemia with a monoclonal IgM cryoglobulin in a patient with Waldenström macroglobulinemia or another underlying B-cell lymphoma. The cryoglobulin is produced by the malignant clone and directly reflects activity of the lymphoproliferative disorder.
Simple monoclonal (type I) cryoglobulinemia is associated with B-cell malignancies, notably Waldenström macroglobulinemia. Detection of a monoclonal IgM cryoglobulin points toward an underlying lymphoproliferative disorder as the primary driver, making management of that disorder the central concern.
In symptomatic type I cryoglobulinemia, the treatment strategy focuses on the underlying hematological malignancy — specifically, combination chemotherapy directed at the lymphoma is a key component of the approach. The complete, structured regimen is available via the link below.
DOI: 10.1016/j.jbspin.2019.01.016
Monoclonal IgM cryoglobulinemia suggests Waldenström macroglobulinemia or another type of lymphoma and monoclonal IgG cryoglobulinemia myeloma or MGUS.
Simple monoclonal (type I) cryoglobulinemia is associated with B-cell malignancies, notably Waldenström macroglobulinemia and myeloma, and with MGUS.
In patients with symptomatic cryoglobulinemia type I, the treatment strategy focuses on the underlying hematological malignancy.
Thus, lymphoma requires combination chemotherapy and myeloma treatment with drugs such as bortezomib, thalidomide, lenalidomide, or alkylating agents.
Exposure to low temperatures exacerbates cryoglobulin formation and should therefore be avoided.
View source ↗